Investment Team
-
Current Companies
-
-
Prior Companies
-
David R. King
-
Joined Quaker BioVentures as Venture Partner in June 2008
-
Previously: CEO and co-founder of BioRexis Pharmaceutical Corporation (acquired by Pfizer), President of Delsys Pharmaceutical Corporation (acquired by Elan), CEO of Principia Pharmaceutical Corp. (acquired by Human Genome Sciences). Prior to becoming a successful serial entrepreneurial, David was a partner with Morgan, Lewis & Bockius LLP, where he founded and led the venture capital and emerging business practice.
-
Current Board Responsibilities: Diasome Pharmaceuticals (Chairman), Pennsylvania Biotechnology Association (PA Bio); University City Science Center
-
Prior Board Participation: Cephalon, 3-Dimensional Pharmaceuticals (acquired by J&J), Morphotek (acquired by Eisai), Innovation Philadelphia, Ursinus College, Snider Entrepreneurial Center of the University of Pennsylvania's Wharton School
-
Education: J.D. from Harvard Law School and undergraduate studies at the University of Pennsylvania
